Πέμπτη 23 Φεβρουαρίου 2017

Rituximab biosimilar granted EU marketing authorisation

The European Commission has approved Truxima, a rituximab biosimilar, for all indications of reference rituximab in the European Union (EU). Truxima is a mAb that targets CD20, a protein found on the surface of most B cells. Overactive B cells can...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lyO6O2
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις